Cargando…
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
The development of familial and sporadic breast cancer is based on genetic alterations of tumour-suppressor genes, for which loss of heterozygosity (LOH) is one mechanism of gene inactivation. To investigate LOH of BRCA1 (17q21) and BRCA2 (13-q12-13) in sporadic breast cancer, polymerase chain react...
Autores principales: | Beckmann, M. W., Picard, F., An, H. X., van Roeyen, C. R., Dominik, S. I., Mosny, D. S., Schnürch, H. G., Bender, H. G., Niederacher, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074503/ https://www.ncbi.nlm.nih.gov/pubmed/8630282 |
Ejemplares similares
-
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017) -
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
por: Cleton-Jansen, A. M., et al.
Publicado: (1995) -
Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma.
por: Bièche, I., et al.
Publicado: (1997) -
Value of the loss of heterozygosity to BRCA1 variant classification
por: Santana dos Santos, Elizabeth, et al.
Publicado: (2022) -
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)